ETONEton Pharmaceuticals, Inc.
$54.73+159% 1Y
$54.73
$14.3552 weeks$64.38
ETON in its own filings
ETON's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
210
Events found in the filings · across 416 filings · the record starts in 2018
- Hard flags
- 1
Hard flags
- Most recent filing
- Sep 28, 2026
Most recent filing · Form 8-K
- Record starts
- Nov 20, 2018
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Change in certifying accountant2 occurrences
- 2025-06-20
- Late periodic reporthistorical
- 2021-11-16
- SEC comment-letter activity12 occurrences
- 2026-01-27
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 28, 2026On September 28, 2026, Eton Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it has launched IMPAVIDO® (miltefosine) capsules.Other event · Form 8-K
- Aug 5, 2026On July 31, 2026, Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) entered into a license agreement (the "Agreement") for a late-stage rare disease product candidate ASN-001 (timolol topical gel) from Auson Pharmaceuticals Inc. ("Auson") for the treatment of proliferating superficial infantile hemangiomas.Material agreement entered · Form 8-K
- Aug 4, 2026On July 31, 2026, Eton Pharmaceuticals, Inc. (the “Company”) appointed Danka Radosavljevic (age 42) as Chief Operating Officer.Director or officer change · Form 8-K
- Jul 29, 2026On July 29, 2026, Eton Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the submission of a prior approval supplement to expand the indication of KHINDIVI® (hydrocortisone) oral solution.Other event · Form 8-K
- May 19, 2026On May 18, 2026, Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) entered into a supply and distribution agreement for the United States commercialization rights to IMPAVIDO® (miltefosine) oral capsules with an affiliate of Knight Therapeutics, Inc. (“Supplier”)Material agreement entered · Form 8-K
- May 1, 2026On May 1, 2026, Eton Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it has launched HEMANGEOL® (propranolol) Oral Solution.Other event · Form 8-K
- Apr 27, 2026On April 27, 2026, Eton Pharmaceuticals, Inc. (the “Company”) issued a press release announcing a pilot study underway for product candidate ET-700, the Company's extended-release formulation of zinc acetate, which will be compared to Galzin® and a placebo for the treatment of Wilson disease.Other event · Form 8-K
- Apr 16, 2026On April 16, 2026, Eton Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the appointment of Judith Matthews as Executive Vice President, Accounting and Finance.Director or officer change · Form 8-K
- Apr 15, 2026On April 9, 2026, Eton Pharmaceuticals, Inc. (the “Company”) entered into a sixth amendment to its credit agreement (the “SWK Credit Agreement”), by and among the Company and SWK Funding LLC (“SWK”)Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Drug Manufacturers, Specialty & Generic
Ranks #34 of 41 by RyuScore